Journal Guide
New England Journal of Medicine Impact Factor 78.5: Publishing Guide
The world's most cited clinical journal - where research changes how medicine is practiced.
78.5
Impact Factor (2024)
<5%
Acceptance Rate
21 days median to first decision
Time to First Decision
What NEJM Publishes
The New England Journal of Medicine (NEJM) is the world's most widely read and cited medical journal, founded in 1812 and published weekly by the Massachusetts Medical Society. With a JIF of 78.5 and a readership of over 600,000 physicians globally, it publishes clinical research that directly changes medical practice. The editorial standard is not scientific excellence alone - it's clinical significance: will physicians treat patients differently after reading this? NEJM is the venue for landmark clinical trials, practice-defining studies, and urgent public health findings. Mechanistic biology, preclinical work, and specialty-specific findings that lack broad clinical practice implications belong elsewhere.
- Randomized controlled trials answering definitive clinical questions about treatments, interventions, or prevention strategies with patient-centered outcomes
- Epidemiological studies with large-scale public health impact, particularly in areas of active clinical debate or urgent need
- Observational studies of high methodological quality that address practice-changing questions where trials are not feasible
- Novel therapeutic or diagnostic approaches with immediate clinical applicability across health systems
- Public health emergencies, outbreak investigations, and health policy studies with urgent clinical relevance
- Genomic or biomarker studies directly tied to treatment decisions and patient outcomes, not purely mechanistic findings
Editor Insight
“We publish research that changes how medicine is practiced. Every paper should answer: should physicians treat patients differently now? If your study is scientifically excellent but doesn't directly affect patient care decisions, a specialty journal will serve it better - and your work better. The journals we compete with are excellent; we have a specific mandate. Bring us the definitive clinical answer, not the promising observation.”
What NEJM Editors Look For
Practice-changing clinical impact
The editorial test at NEJM is simple: will a physician change how they treat patients after reading this? Not 'consider this as a possibility' - actually change practice. If your study is scientifically interesting but doesn't directly shift clinical decision-making, a specialty journal is the better target.
Hard patient-centered endpoints
Mortality, major cardiovascular events, disease-free survival, hospitalization, functional outcomes. Biomarker-only studies don't meet NEJM's bar unless the biomarker has been validated as a surrogate for outcomes that matter to patients and clinicians.
Large, adequately powered studies
NEJM rarely publishes underpowered pilot data. If you have Phase 2 results with an exciting signal, complete the Phase 3 before submitting. The journal is where you publish the definitive answer - not the promising question.
Methodological rigor that holds up to intense scrutiny
Randomization, blinding, intention-to-treat analysis, pre-registration, transparent data access. NEJM employs dedicated statisticians who review all accepted manuscripts. Protocol deviations must be documented and justified. There's no room for shortcuts in design or reporting.
Broad relevance across healthcare systems
Findings should apply beyond one institution or one country. Multi-center, international trials have a structural advantage. If results rely on specific local conditions or resources, generalizability becomes an editorial concern.
Independence from sponsor influence
Industry-sponsored trials need explicit independence safeguards: data access rights, author publication control, pre-specified primary outcomes that weren't changed after unblinding. NEJM has been burned before. They look hard at sponsor relationships.
Why Papers Get Rejected
These patterns appear repeatedly in manuscripts that don't make it past NEJM's editorial review:
Submitting pilot or Phase 2 data as an Original Article
NEJM exists for definitive clinical answers. A 100-patient study showing a promising trend belongs in a specialty journal. Come back with the full trial. Submitting too early wastes time and signals misjudgment about editorial standards.
Focusing on biomarker or surrogate endpoints without outcome data
Demonstrating that a drug improves a biomarker is far less compelling than showing it prevents myocardial infarctions or extends survival. NEJM consistently prioritizes patient outcomes over mechanistic signals.
Burying clinical implications in the discussion
Busy physicians read abstracts first. Your structured abstract needs to make the practice implication immediately obvious: what should change, for which patients, how much does it matter. Vague conclusions dilute impact.
Protocol deviations without transparent justification
NEJM cross-references registered protocols with submitted papers systematically. Any deviation from the pre-specified primary outcome or analysis plan requires documented justification. Post-hoc subgroup analyses should be labeled exploratory.
Incomplete adverse event reporting
Selective safety reporting is both an ethical concern and an editorial dealbreaker. Full adverse event tables, serious adverse events, discontinuations, and deaths must be reported completely regardless of whether they complicate the narrative.
Single-center data without multi-site validation
Results from one institution raise generalizability questions. NEJM favors multi-center designs. Single-center trials can publish in NEJM, but they face harder questions about whether the results reflect local expertise rather than generalizable effects.
Does your manuscript avoid these patterns?
The quick diagnostic reads your full manuscript against NEJM's criteria and flags the specific issues most likely to cause rejection.
Insider Tips from NEJM Authors
The 'Monday morning' test
NEJM editors literally ask: will a doctor change how they practice on Monday after reading this? If the change is theoretical or marginal, the paper may be excellent but it belongs in Annals of Internal Medicine, not NEJM.
Negative trials can and do publish here
A well-designed trial that definitively shows a treatment doesn't work is exactly what NEJM wants. These prevent use of ineffective therapies at scale. Don't assume a null result disqualifies you - the design quality matters more.
NEJM has the fastest editorial process at this level
They understand clinical findings can be time-sensitive. Median first decision is 21 days, which is remarkable for a journal at this tier. If your results have public health urgency, say so in your cover letter.
Patient-reported outcomes are increasingly valued
Quality of life, functional status, symptom burden: these complement hard endpoints. A drug that extends survival but causes significant toxicity is a more complicated story. Including patient-reported outcomes makes the clinical picture more complete.
Pre-registration is examined closely
NEJM's statistical team compares your submission against your ClinicalTrials.gov or ISRCTN registration. Outcome changes, added subgroups, and altered analysis populations get flagged. Keep your registration updated as the trial evolves, with documented rationale for any changes.
Editorials and perspectives are by invitation only
Don't waste time drafting unsolicited opinion pieces. If editors like your work, they'll commission an editorial to accompany it. Focus all your energy on Original Articles or Brief Reports.
Data sharing is expected
NEJM has a formal data-sharing policy. Trials with primary results must include a data availability statement. Plan your data sharing infrastructure before submission, not after acceptance.
ICMJE authorship requirements are strictly enforced
All listed authors must have contributed to conception/design, data acquisition/analysis, or interpretation - plus drafting or critically revising the manuscript. Gift authorship is taken seriously. Be prepared to define each author's contribution.
The NEJM Submission Process
Prepare a complete, CONSORT-compliant manuscript
Preparation phaseFor trials: CONSORT checklist (or relevant reporting guideline), trial registration number, data sharing statement, structured abstract of ≤250 words. For observational studies: STROBE checklist. Methods section must be complete and replicable.
Submit via NEJM online portal
Submission stepUpload manuscript, cover letter explaining why this paper is right for NEJM and why now, conflict of interest disclosures for all authors, IRB/ethics approval. Cover letter should be direct - one paragraph on the clinical question, one on the answer, one on the practice implication.
Initial editorial triage
~7-10 daysSenior editors assess scope, clinical significance, and methodological credibility. Desk rejection rate is approximately 80% - higher than most journals at this tier. Papers that make it past triage have clear, large-scale clinical relevance and strong methods.
Statistical review (concurrent with peer review)
Concurrent with peer reviewAll papers advancing to peer review undergo statistical analysis review. NEJM's in-house statisticians check sample size calculations, analysis plan adherence, handling of missing data, and multiplicity corrections.
External peer review
~10-14 days after triageTwo to three clinical experts and a methodologist. Reviewers focus on clinical validity, generalizability, completeness of reporting, and safety data. Review comments tend to be specific and addressable.
Decision and revision
21 days median to first decisionNEJM makes prompt decisions. Revisions are typically focused - not open-ended requests for more experiments. Respond to every reviewer point precisely and completely. Second submissions get a second statistical review.
NEJM by the Numbers
| 2024 Impact Factor (JCR 2024)(Rank 2/332 in Medicine, General & Internal) | 78.5 |
| 5-Year Impact Factor(Clarivate JCR 2024) | 84.9 |
| Quartile(Top journal in General & Internal Medicine) | Q1 |
| Acceptance rate | <5% |
| Desk rejection rate | ~80% |
| Post-review acceptance | ~25% of reviewed manuscripts |
| Median first decision | 21 days |
| Readership | 600,000+ physicians worldwide |
| Issues per year | 52 (weekly) |
| Founded(Published by Massachusetts Medical Society) | 1812 |
Before you submit
NEJM accepts a small fraction of submissions. Make your attempt count.
The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to NEJM. ~30 minutes.
Article Types
Original Article
2,700 words (main text), 4-5 tables or figuresFull reports of clinical research - randomized trials, major observational studies, pivotal Phase 3 therapeutic data. Structured abstract required. The primary submission type.
Brief Report
1,200 words, 2 tables or figuresConcise reports of important clinical findings that don't require full Original Article length. Single-center case series or preliminary outcome data may fit here.
Special Article
Variable, by invitation or editorial discussionImportant topics that fall outside the standard research format - health policy analyses, major systematic reviews with direct practice implications, methodological advances.
Case Records of the Massachusetts General Hospital
By invitationClinical problem-solving cases presented in the MGH clinicopathological conference format. Invited by editors; not open for unsolicited submission.
Landmark NEJM Papers
Papers that defined fields and changed science:
- First public demonstration of ether anesthesia (1846) - arguably the most important medical advance in the journal's history
- SPRINT trial: intensive blood-pressure control prevents cardiovascular events - changed hypertension management guidelines worldwide (2015)
- Efficacy and safety of mRNA-1273 COVID-19 vaccine - defined the pandemic response (2020)
- Gleevec (imatinib) in chronic myeloid leukemia - the first targeted cancer therapy to reach landmark trial status (2001)
- Framingham Heart Study foundational papers - established cardiovascular risk factors still used in clinical practice (1961 onward)
Preparing a NEJM Submission?
Get pre-submission feedback from reviewers who've published in NEJM and know exactly what editors look for.
Run Free Readiness ScanNeed expert depth? Human review from $1,000
Primary Fields
Related Journal Guides
- Publishing in The Lancet
- Publishing in JAMA (Journal of the American Medical Association)
- Publishing in The BMJ (British Medical Journal)
- Publishing in Circulation
- Publishing in European Heart Journal
Related Articles
- Desk Rejection: What It Means, Why It Happens, and What to Do Next
- How to Respond to Reviewer Comments (Without Losing Your Mind)
- How to Choose the Right Journal for Your Paper (A Practical Guide)
- Pre-Submission Scientific Review: What It Costs, When It Works, and When to Skip It
Ready to submit to NEJM?
A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what NEJM editors look for.
Avoid Desk Rejection
Get expert pre-submission review before you submit to NEJM. 3-7 day turnaround.
Manuscript Rejected?
Expert revision help to strengthen your manuscript and resubmit with confidence.
Reviewer Response Help
Get expert guidance crafting your response to NEJM reviewers.
Need field-expert depth? Human review from $1,000